Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al

J Immunother Cancer. 2023 Mar;11(3):e006784. doi: 10.1136/jitc-2023-006784.

Lena Immisch^{1

2

3}, George Papafotiou^{1

2

3}, Oliver Popp⁴, Philipp Mertins^{4

5}, Thomas Blankenstein^{4

5}, Gerald Willimsky^{6

2

3

5}

¹ Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
² German Cancer Research Center, Heidelberg, Germany.
³ German Cancer Consortium, partner site Berlin, Berlin, Germany.
⁴ Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
⁵ Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
⁶ Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany [email protected].

No abstract available

Keywords: Antigens, Neoplasm; Immunotherapy; Immunotherapy, Adoptive.

Publication types